Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real-World Data in Japan
Masaya Sakamoto¹
1) Department of Medicine, International University of Health and Welfare, Japan
Yamazaki Michiko ¹,²、Takebe Tohru³、Hosokawa Masaya⁴、Saika Tomoya ¹、Nakao Yutaka⁵、Ikeda Shunya² 、
1)Patient Engagement Business Domain, KAKEHASHI Inc., Japan
2)Graduate School of Medicine/ Graduate School of Public Health, International University of Health and Welfare, Japan
3)Patient Engagement PRO/RWE Business Development, KAKEHASHI Inc., Japan
4)Patient Engagement RWD Analytics, KAKEHASHI Inc., Japan 5)President, KAKEHASHI Inc., Japan
要旨
We analyzed pharmacy data in Japan (Musubi, Nov 2022–Oct 2023) for 91,230 diabetes patients, 72.7% aged ≥65 years. Glimepiride (80.1%), gliclazide (16.3%), and glibenclamide (3.6%) were most prescribed. Among elderly patients, 25.0% and 7.8% exceeded guideline doses for glimepiride and gliclazide, while 77.5% received glibenclamide. Concomitant use of DPP-4 inhibitors, biguanides, and SGLT-2 inhibitors was common. Findings highlight frequent high-dose or inappropriate SU use in the elderly, emphasizing the need for safer prescribing.
